• AstraZeneca completed an exclusive global license deal with Dizal for lung cancer drug Zegfrovy, securing worldwide development and commercialization rights.
• Deal terms include USD 600 million upfront, up to USD 900 million in development, regulatory, sales milestones, tiered royalties on global sales.
• Zegfrovy is approved in the US, China for second-line EGFR exon 20 insertion NSCLC; US launch planned for Q4 2026.
• FDA accepted a supplemental filing for first-line use, backed by Phase III WU-KONG28 results; Breakthrough Therapy Designation granted in US, China.
• Transaction leaves 2026 financial guidance unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.